Article Drug pipeline

Front-Line Covalent BTK Inhibitor + Venetoclax ± Obinutuzumab: A New Triple Threat?

Emerging front-line chronic lymphocytic leukemia (CLL) treatment options combine covalent BTK inhibitors with venetoclax and obinutuzumab, prompting new considerations around clinical benefit, risk, and cost compared…

By Richa Madurkar

Article Cost and utilization

The New Cancer Curveball: Why Rising Rates Among Working Adults Could Hit Your Wallet Too

Health insurance premiums are projected to see their largest increase in 15 years — and rising cancer rates among working-age adults are partly to blame. Here’s…

By Corey Wise

Article Supportive care

3 Ways Malnutrition in Cancer Care is Driving up Costs for Health Plans

Malnutrition in cancer care is more than a clinical issue; it’s a financial one. Here are three areas where malnutrition has the biggest financial impact on…

Article Supportive care

The Hidden Cost of Cancer: Financial Toxicity

When we talk about “toxicity” in cancer care, most think of the physical side effects of treatment. But there’s another form that can be just as…

Article Drug pipeline

Translating ASCO Insights Into Action: A Payer’s Guide to What’s Next in Oncology

By Laura R. Bobolts